Joan B. Soriano, Julio Ancochea, Bartolomé R. Celli
European Respiratory Journal 2019; DOI: 10.1183/13993003.02047-2019
Since its inception in 2002, World COPD Day is celebrated to raise awareness and reduce COPD-related burden. In spite of this global effort, COPD remains poorly recognised. Indeed, Boehm, et al. , using Google Trends noted the rather limited global awareness of COPD, which rates 8th within the top ten causes of disease burden searched. On a positive note, they identified a seasonal trend with a peak activity in November, that could be related to the increased incidence of acute exacerbations during the winter period, but it may also reflect the “noise” created by initiatives like the COPD Awareness Month and World COPD Day. The 2019 theme for World COPD Day will be “All Together to End COPD”, to be celebrated on November 20, 2019. Optimistically, recent evidence of projected global COPD mortality rates indicates this theme to actually be more than wishful thinking.
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: JBS participated in speaking activities, advisory committees and consultancies during the period 2015–2019 sponsored by: Almirall, AstraZeneca, Boehringer-Ingelheim, CHEST, Chiesi, ERS, GEBRO, Grifols, GSK, Linde, Lipopharma, Mundipharma, Novartis, Pfizer, RiRL, Rovi, Sandoz, SEPAR and Takeda. JBS declares not receiving ever, directly or indirectly, funding from the tobacco industry or its affiliates.
Conflict of interest: Julio Ancochea
Conflict of interest: Dr. Celli reports personal fees and other from Astra Zeneca, personal fees from GlaxoSmithKline, personal fees from Boehringer Ingelheim, personal fees from Novartis, personal fees from Sanofi Aventis and personal fess form Menarini other from outside the submitted work.